Publications by authors named "H Nishizaka"
Background: To analyse the subsequent clinical course of patients with rheumatoid arthritis (RA) who either continued or discontinued biologic agents after hospitalization for infections.
Methods: We retrospectively reviewed the clinical records of 230 RA patients with 307 hospitalizations for infections under biologic therapy between September 2008 and May 2014 in 15 institutions for up to 18 months after discharge. The risks of RA flares and subsequent hospitalizations for infections from 61 days to 18 months after discharge were evaluated.
We studied the clinico-pathological differences among PR3-ANCA-positive granulomatosis with polyangiitis (PR3-GPA), MPO-ANCA-positive GPA (MPO-GPA) and microscopic polyangiitis (MPA). ANCA-associated vasculitis (AAV) was classified using the European Medicines Agency classification. We retrospectively analyzed 38 patients with GPA and 41 with MPA treated in eight hospitals in Japan.
View Article and Find Full Text PDFObjectives: This study aimed to evaluate the remission in rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ), based on prospectively registered data in clinical practice.
Methods: We studied 114 consecutive RA patients treated with TCZ for an average of 3.5 years.
Article Synopsis
- This study evaluated the effectiveness of tocilizumab (TCZ) in achieving remission in rheumatoid arthritis (RA) patients, analyzing data from 114 patients treated for about 3.5 years.
- Results showed that 66.7% of patients achieved a DAS28-ESR score of less than 2.6, indicating improvement, and 35.1% met the ACR/EULAR remission criteria, with a better response in biologics-naïve patients.
- The retention rate for patients continuing treatment after 36 months was 68.2%, highlighting TCZ's effectiveness in both previously treated and untreated RA patients.